Clinical Trial: S9624 Ifosfamide in Treating Patients With Meningeal Tumors
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: S9624: Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors
Brief Summary:
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically.
Detailed Summary:
OBJECTIVES:
- Estimate failure free survival, overall survival, and response in patients with residual or recurrent/progressive aggressive meningeal tumors (malignant meningioma, hemangiopericytoma, and primary nervous system sarcoma) treated with ifosfamide.
- Evaluate toxicities of ifosfamide in this patient population.
OUTLINE: All patients receive ifosfamide IV continuously over 72 hours on days 1-3 of each 21 day treatment course. Patients are evaluated for response/progression after every 2 courses. Patients with stable disease receive up to 8 courses of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year, then every 6 months thereafter.
PROJECTED ACCRUAL: Approximately 35 patients will be accrued for this study.
Sponsor: Southwest Oncology Group
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Southwest Oncology Group
Dates:
Date Received: November 1, 1999
Date Started: July 1998
Date Completion:
Last Updated: November 7, 2013
Last Verified: November 2013